Kumar R, Smeds J, Lundh Rozell B, Hemminki K
Department of Biosciences, Karolinska Institute, Novum, Huddinge, Sweden.
Melanoma Res. 1999 Apr;9(2):138-47. doi: 10.1097/00008390-199904000-00005.
Loss of heterozygosity (LOH) was determined in 45 sporadic primary melanomas at six polymorphic microsatellite markers that flank the INK4a (p16-p14ARF) locus on chromosome 9p21. We also determined allelic loss at two markers on chromosome 9q and two markers at the Rb locus on chromosome 13. Homozygous deletion of the p16 and p14ARF genes was determined by a fluorescent-based quantitative multiplex polymerase chain reaction method. LOH at one or more polymorphic microsatellite markers on locus 9p21 was found in 32 of the melanomas (71%). The highest proportion of LOH was found at markers D9S736 and D9S104, which are telomeric and centromeric to the INK4 locus, respectively. Five melanomas showed LOH at all the analysed markers located on chromosome 9p21. LOH at markers D9S942 and D9S974, which are located close to the p16 and p14ARF genes, was found in 39% and 46% of melanomas, respectively. Analysis of the marker D9S257 on 9q22.1 showed LOH in 13 melanomas (44% of the informative cases). A subset of melanomas with LOH at the INK4 locus also carried inactivating mutations within the p16 coding sequence. Four melanomas carried homozygous deletions at the p16-p14ARF locus. Our results suggest, besides the involvement of the INK4 locus in sporadic melanomas, the possibility of the existence of additional tumour suppressor loci on chromosome 9.
在45例散发的原发性黑色素瘤中,检测了位于9号染色体p21区域INK4a(p16-p14ARF)基因座两侧的6个多态性微卫星标记的杂合性缺失(LOH)。我们还检测了9号染色体上两个标记以及13号染色体上Rb基因座的两个标记的等位基因缺失情况。通过基于荧光的定量多重聚合酶链反应方法确定了p16和p14ARF基因的纯合缺失。在32例黑色素瘤(71%)中发现9号染色体p21基因座上一个或多个多态性微卫星标记存在LOH。在分别位于INK4基因座端粒和着丝粒位置的标记D9S736和D9S104处发现的LOH比例最高。5例黑色素瘤在9号染色体p21上所有分析的标记处均显示LOH。在分别靠近p16和p14ARF基因的标记D9S942和D9S974处,分别在39%和46%的黑色素瘤中发现LOH。对9q22.1上标记D9S257的分析显示,13例黑色素瘤(44%的信息病例)存在LOH。INK4基因座存在LOH的一部分黑色素瘤在p16编码序列内也携带失活突变。4例黑色素瘤在p16-p14ARF基因座存在纯合缺失。我们的结果表明,除了INK4基因座参与散发性黑色素瘤外,9号染色体上还可能存在其他肿瘤抑制基因座。